WO2004002461A3 - Nouvelle combinaison - Google Patents

Nouvelle combinaison Download PDF

Info

Publication number
WO2004002461A3
WO2004002461A3 PCT/IB2003/002657 IB0302657W WO2004002461A3 WO 2004002461 A3 WO2004002461 A3 WO 2004002461A3 IB 0302657 W IB0302657 W IB 0302657W WO 2004002461 A3 WO2004002461 A3 WO 2004002461A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiotensin
combination
receptor antagonists
pde5 inhibitors
pde5
Prior art date
Application number
PCT/IB2003/002657
Other languages
English (en)
Other versions
WO2004002461A2 (fr
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer Ltd
David Nathan Abraham Fox
Bernadette Hughes
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, David Nathan Abraham Fox, Bernadette Hughes, Pfizer filed Critical Pfizer Ltd
Priority to KR10-2004-7021041A priority Critical patent/KR20050013156A/ko
Priority to EP03761725A priority patent/EP1524996A2/fr
Priority to AU2003242895A priority patent/AU2003242895A1/en
Priority to CA002491002A priority patent/CA2491002A1/fr
Priority to MXPA04012569A priority patent/MXPA04012569A/es
Priority to BR0312030-9A priority patent/BR0312030A/pt
Priority to JP2004517093A priority patent/JP2005531627A/ja
Publication of WO2004002461A2 publication Critical patent/WO2004002461A2/fr
Publication of WO2004002461A3 publication Critical patent/WO2004002461A3/fr
Priority to NO20050400A priority patent/NO20050400L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des combinaisons contenant a) un inhibiteur de phosphodiestérase type 5 (PDE5) spécifique à la guanosine monophosphate cyclique (cGMP) et b) un antagoniste de récepteur d'angiotensine II, lesquelles sont utiles dans le traitement de l'hypertension.
PCT/IB2003/002657 2002-06-26 2003-06-16 Nouvelle combinaison WO2004002461A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR10-2004-7021041A KR20050013156A (ko) 2002-06-26 2003-06-16 신규 조합 제제
EP03761725A EP1524996A2 (fr) 2002-06-26 2003-06-16 Combinaison d'inhibiteurs de la pde5 avec des antagonistes des recepteurs a l'angiotensine ii
AU2003242895A AU2003242895A1 (en) 2002-06-26 2003-06-16 Combination of PDE5 inhibitors with angiotensin II receptor antagonists
CA002491002A CA2491002A1 (fr) 2002-06-26 2003-06-16 Nouvelle combinaison
MXPA04012569A MXPA04012569A (es) 2002-06-26 2003-06-16 Combinacion de inhibidores de fosfodiesteresa tipo 5(pde5) con antagonistas del receptor de angiotensina ii.
BR0312030-9A BR0312030A (pt) 2002-06-26 2003-06-16 Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii
JP2004517093A JP2005531627A (ja) 2002-06-26 2003-06-16 新規混合医薬
NO20050400A NO20050400L (no) 2002-06-26 2005-01-25 Nytt kombinasjonspreparat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0214784.1 2002-06-26
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination

Publications (2)

Publication Number Publication Date
WO2004002461A2 WO2004002461A2 (fr) 2004-01-08
WO2004002461A3 true WO2004002461A3 (fr) 2004-05-13

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/002657 WO2004002461A2 (fr) 2002-06-26 2003-06-16 Nouvelle combinaison

Country Status (20)

Country Link
EP (1) EP1524996A2 (fr)
JP (1) JP2005531627A (fr)
KR (1) KR20050013156A (fr)
CN (1) CN1662257A (fr)
AR (1) AR040337A1 (fr)
AU (1) AU2003242895A1 (fr)
BR (1) BR0312030A (fr)
CA (1) CA2491002A1 (fr)
GB (1) GB0214784D0 (fr)
GT (1) GT200300124A (fr)
MX (1) MXPA04012569A (fr)
NO (1) NO20050400L (fr)
PA (1) PA8575501A1 (fr)
PE (1) PE20040868A1 (fr)
PL (1) PL375079A1 (fr)
RU (1) RU2004136276A (fr)
TW (1) TW200404546A (fr)
UY (1) UY27863A1 (fr)
WO (1) WO2004002461A2 (fr)
ZA (1) ZA200409532B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
JPWO2004036162A1 (ja) * 2002-07-26 2006-02-16 オリンパス株式会社 画像処理システム
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
RU2369392C2 (ru) * 2005-06-10 2009-10-10 Донг-А Фармасьютикал. Ко., Лтд. Средство для профилактики и лечения заболеваний печени, содержащее производное пиразолопиримидинона
WO2007010337A2 (fr) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Utilisation d'inhibiteurs de phosphodiesterase type 5 pour la prevention et le traitement de maladies ou de troubles, et systemes d'administration associes
JP2009512711A (ja) * 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463756A1 (fr) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidones comme agents antiangineux
WO1995019978A1 (fr) * 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Derives tetracycliques, leurs procedes de preparation et leur utilisation
WO1999024433A1 (fr) * 1997-11-12 1999-05-20 Bayer Aktiengesellschaft Imidazotriazinones a substitution 2-phenyle utilisees comme inhibiteurs des phosphodiesterases
WO2001027112A1 (fr) * 1999-10-11 2001-04-19 Pfizer Limited Pyrimidine-7-ones 5-(2-substitutees-5-heterocyclylsulphonylpyride-3-yl)-dihydropyrazolo[4,3-d] servant d'inhibiteurs de la phosphodiesterase
WO2001027113A2 (fr) * 1999-10-11 2001-04-19 Pfizer Limited Composes actifs au plan pharmaceutique
WO2002013798A2 (fr) * 2000-08-11 2002-02-21 Pfizer Limited Traitement du syndrome de la resistance a l'insuline

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463756A1 (fr) * 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidones comme agents antiangineux
WO1995019978A1 (fr) * 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Derives tetracycliques, leurs procedes de preparation et leur utilisation
WO1999024433A1 (fr) * 1997-11-12 1999-05-20 Bayer Aktiengesellschaft Imidazotriazinones a substitution 2-phenyle utilisees comme inhibiteurs des phosphodiesterases
WO2001027112A1 (fr) * 1999-10-11 2001-04-19 Pfizer Limited Pyrimidine-7-ones 5-(2-substitutees-5-heterocyclylsulphonylpyride-3-yl)-dihydropyrazolo[4,3-d] servant d'inhibiteurs de la phosphodiesterase
WO2001027113A2 (fr) * 1999-10-11 2001-04-19 Pfizer Limited Composes actifs au plan pharmaceutique
WO2002013798A2 (fr) * 2000-08-11 2002-02-21 Pfizer Limited Traitement du syndrome de la resistance a l'insuline

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUDAVARI S ET AL: "The Merck Index", 2001, MERCK INDEX. ENCYCLOPEDIA OF CHEMICALS, DRUGS, AND BIOLOGICALS, RAHWAY, MERCK & CO, US, VOL. ED. 13, PAGE(S) 291, 645, 5099, 1000, 1223, 1224, 1502, 1628, 1629, 1767, XP002259715 *
FOGARI, ROBERTO (1) ET AL: "Different effect of valsartan and lisinopril on sildenafil use in hypertensive men with erectile dysfunction.", AMERICAN JOURNAL OF HYPERTENSION, (APRIL, 2002) VOL. 15, NO. 4 PART 2, PP 37A. HTTP://WWW.AJH-US.ORG. PRINT. MEETING INFO.: SEVENTEENTH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN SOCIETY OF HYPERTENSION NEW YORK, N.Y., USA MAY 14-18, 2002, XP001131927 *

Also Published As

Publication number Publication date
BR0312030A (pt) 2005-03-22
WO2004002461A2 (fr) 2004-01-08
JP2005531627A (ja) 2005-10-20
GB0214784D0 (en) 2002-08-07
PA8575501A1 (es) 2003-12-30
KR20050013156A (ko) 2005-02-02
ZA200409532B (en) 2006-06-28
CN1662257A (zh) 2005-08-31
GT200300124A (es) 2004-03-17
PE20040868A1 (es) 2004-11-25
MXPA04012569A (es) 2005-04-19
EP1524996A2 (fr) 2005-04-27
NO20050400L (no) 2005-03-29
AR040337A1 (es) 2005-03-30
AU2003242895A1 (en) 2004-01-19
RU2004136276A (ru) 2005-09-10
CA2491002A1 (fr) 2004-01-08
UY27863A1 (es) 2003-12-31
PL375079A1 (en) 2005-11-14
TW200404546A (en) 2004-04-01

Similar Documents

Publication Publication Date Title
NO20050400L (no) Nytt kombinasjonspreparat
EP1085871A4 (fr) INHIBITEURS QUINAZOLINONE DE LA PHOSPHODIESTERASE cGMP
EP1404337A4 (fr) Inhibiteurs de quinazoline et de pyrido 2,3-d|pyrimidine de la phosphodiesterase (pde) 7
HK1056550A1 (en) Xanthine phosphodiesterase v inhibitors
WO2003017936A3 (fr) Utilisation d'inhibiteurs de la dppiv utilises comme agents diuretiques et anti-hypertenseurs
MY135909A (en) Treatment of pulmonary hypertension
WO2006023944A3 (fr) Administration pulmonaire d'inhibiteurs de phosphodiesterase de type 5
AU2001285163A1 (en) Quinoline inhibitors of cgmp phosphodiesterase
WO2002102313A3 (fr) Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7
AU2003265349A1 (en) Pyrrolotriazine kinase inhibitors
AU2003276648A1 (en) Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
HK1071570A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
NO20021783D0 (no) Alkylamino-substituerte bicykliske nitrogen-heterocykler som inhibitorer for P38-protein-kinase
HK1071569A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
NO20021781D0 (no) Heteroalkylamino-substituerte bicykliske nitrogenheterocykler som inhibitorer for P38-proteinkinase
HK1069970A1 (en) Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
MXPA04000586A (es) Combinacion de un atagonista del receptor de aldosterona con un inhibidor de la hmg coa reductasa.
WO2003099194A3 (fr) Nouvelle combinaison
IL163958A0 (en) Anxiolytic agents with reduced sedative and ataxideffects
AU2003249658A1 (en) Xanthine phosphodiesterase v inhibitor polymorphs
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
WO2005042022A3 (fr) Combinaison nouvelle
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
WO2005116195A3 (fr) Methode d'identification de modulateurs de pde5
DOP2003000649A (es) Nueva combinacion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004/09532

Country of ref document: ZA

Ref document number: 536827

Country of ref document: NZ

Ref document number: 200409532

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 3759/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003242895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/012569

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1-2004-502072

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003761725

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003814574X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004517093

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2491002

Country of ref document: CA

Ref document number: 375079

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 1020047021041

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1200500093

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020047021041

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003761725

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003761725

Country of ref document: EP